Vendor Intelligence Report: Biolongevity Labs

Executive summary

Across 33 Finnrick lab tests, Biolongevity Labs posts 25 pass / 8 fail, for an overall pass rate of 76%. The record is mixed rather than uniformly poor: GHK-Cu is the cleanest tested signal, Retatrutide is comparatively strong on assay performance, and BPC-157 is the product-specific weak point that fails more often than it passes. The full data set matters because Biolongevity is a vendor to read peptide-by-peptide, not as a single safe/unsafe verdict.

The business is not anonymous. The investigation ties the peptide storefront to an Akron-area F2 Nutrition identity with named public operators and a renewed canonical domain. The due-diligence caveat is sharper: retained business-start evidence and the newer BioLongevity web trail describe different histories, while privacy-policy/address and corporate-suffix details create cleanup issues for buyers trying to reconcile the public record.

Quality claims require a separate filter. Biolongevity presents U.S.-manufacturing, third-party-testing, and multi-lab review language, but Finnrick's retained vial trail shows white-label presentation and no batch IDs across the tested sample set. That weakens the buyer's ability to match a vial to a lab-direct COA, and it leaves SafeCert independence and lot-level retrieval as live verification items rather than settled assurance.

The report also maps a large promotion environment: founder media, vendor subreddit activity, coupon pages, affiliate IDs, referral parameters, and personal discount codes, including independent-looking posts where disclosure was not consistently visible. Regulatory searches found no vendor-specific FDA warning letter, but Retatrutide remains continuity-sensitive because it is an unapproved GLP-1/GIP/GCGR candidate sold through a research-use channel.

Inside the full report:

• Per-product Finnrick pass/fail analysis and methodology-divergence charts for all 5 tested products
• F2 Nutrition / BioLongevity entity, address, BBB, and domain-renewal trail
• Vial traceability review covering white-label presentation, missing batch IDs, and COA-matching limits
• SafeCert Labs and “three independent laboratories” verification questions
• Affiliate and promotion-network scan across X, Reddit, coupon sites, and tracked referral links
• Risk matrix covering BPC-157, Retatrutide continuity, regulatory posture, complaints, and channel verification

Risk assessment

• BPC-157 quality-control risk — high: BPC-157 is fail-heavy in Finnrick testing: 11 tests, 5 pass / 6 fail, Finnrick rating 46.8%.
• Vial-level traceability and manufacturing-claim risk — high: All Finnrick-tested BPC-157, Retatrutide, GHK-Cu, Ipamorelin and PT-141 samples in the record lacked batch IDs/white-label presentation; U.S.-manufacturing claims remain unverified.
• Retatrutide regulatory-continuity risk — high: Retatrutide tests comparatively well (80.57%), but it remains an unapproved GLP-1/GIP/GCGR candidate exposed to RUO enforcement and supply disruption.
• Affiliate-promotion and channel-verification risk — high: The scan found 30 promoter/coupon/reddit/review channels, including many aff_id/ref-code posts without disclosure and no documented authorized-channel list.
• COA verification and independence risk — medium: Biolongevity says compounds are reviewed by three independent labs including SafeCert, but SafeCert independence and lab-retrievable, vial-matched COAs were not verified.
• Customer-service responsiveness risk — medium: Retained BBB evidence shows a C+ profile with one unresolved delivery/refund complaint; a Reddit complaint alleges similar refund friction at lower confidence.